Search This Blog

Tuesday, June 28, 2022

Basilea: positive results of phase 3 study with ceftobiprole in Staphylococcus aureus bacteremia

 

  • Ceftobiprole met primary and secondary efficacy endpoints
  • Basilea plans to submit a New Drug Application (NDA) in the U.S. around year end 2022
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)